FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab-kcqx,
The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab-kcqx,
What's Your Reaction?
